Jupiter Neurosciences, Inc. (JUNS) AI Stock Analysis

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company that develops therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates through two segments: Pharmaceutical Operations and Premium Nutritional Supplements. Its drug pipeline includes JNS115 in Phase IIa clinical trials for Parkinson's disease, alongside Phase II candidates JNS108 for mild cognitive impairment/early Alzheimer's disease, JNS102 for mucopolysaccharidosis type 1, and JNS107 for mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company commercializes and sells GLO, MND, and PWR products under the Nugevia brand name.

Revenue has decreased substantially over several fiscal years, dropping from $1.1M in FY2020 to $638,037 in FY2021, $233,281 in FY2022, and $21,796 in FY2025. This reflects a revenue compound annual growth rate of -73.2% between FY2020 and FY2025. Gross margin contracted to 80.6% in FY2025 compared to 100.0% in previous reported fiscal years. Research and development expenses reached $2.1M in FY2025, contributing to an operating margin of -40873.2% and a net loss of -$8.6M. For the trailing twelve months ended June 30, 2026, revenue was $64,693 with an operating margin of -11313.5% and an EPS of -$18.94.

As of June 30, 2026, Jupiter Neurosciences held $1.5M in cash and short-term investments and $1.7M in total debt, resulting in net debt of $227,202. The company faces negative equity, with shareholders' equity of -$365,966 against total assets of $3.7M. Its current ratio stood at 0.66. Operating cash flow was -$5.4M in FY2025, matching free cash flow of -$5.4M alongside minimal capital expenditures of $4. To support operations, the share count increased 371.3% over five years.

JUNS closed at $2.90 on October 16, 2026, representing a 97.6% one-year decline compared to a 16.8% gain for the S&P 500 (SPY). The company trades at an enterprise value of $4.1M and a forward P/E of 28.7x, which is above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 59.2x and EV-to-revenue multiple of 64.0x also stand well above the US-listed Healthcare peer median price-to-sales of 4.1x. The stock trades 88.0% below its 200-day moving average.

One analyst covering the stock models next fiscal year revenue of $11.4M, representing estimated revenue growth of 6418.3%, along with an estimated EPS of $0.06. The mean price target is $30.00, which represents a 932.7% premium over the last close of $2.90. Over the last four quarters, the company beat EPS estimates once. The next earnings date is November 13, 2026.

This page is an AI-written research summary of Jupiter Neurosciences, Inc. (JUNS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: JUNS income statement, JUNS balance sheet, JUNS key metrics, JUNS analyst forecast, JUNS chart. See the JUNS stock overview for the latest quote and news.